Úvodní slovo prof. MUDr. Petra Urbánka, CSc. spolueditora tohoto suplementa časopisu Vnitřní lékařství. Chronická hepatitida C - začátek konce jednoho onemocnění?

Petr Urbánek

Vnitr Lek 2015, 61(Suppl 4):5  

Approach to patients with liver diseases

Radan Brůha

Vnitr Lek 2015, 61(Suppl 4):6-12  

In recent years the most frequent cause of chronic liver diseases in western countries has become Non-alcoholic hepatic steatosis/steatohepatitis (NAFLD/NASH). It is part or immediate manifestation of metabolic syndrome. A crucial task for the future is to diagnose this hepatic injury to a greater extent and cooperate with other internal medicine physicians in the care of patients with NAFLD. It has been clearly proven that it is not a benign disease, as assumed in the past. Non-alcoholic steatohepatitis can have serious consequences for the patient and it needs to be actively searched for. The still prevalent notion that normal liver tests in patients...

Cirrhosis of the liver and HCV

Václav Hejda

Vnitr Lek 2015, 61(Suppl 4):13-23  

Cirrhosis of the liver is the final morphological stage of most liver diseases with subsequent risk of decompensation and complications (portal hypertension, HCC). At present it is apparent, however, that a dynamic two-way process is involved with a possibility of further progression, but also regression of fibrosis/cirrhosis provided that causal treatment of the basic hepatologic disease is possible. Determining the stage and level of fibrosis progression is absolutely key to further care of the patient, establishment of the prognosis and possibly the treatment indication. At present non-invasive methods of liver fibrosis are the preferred option...

Possibilities of IFN-free therapy of hepatitis C

Petr Husa

Vnitr Lek 2015, 61(Suppl 4):24-29  

Chronic hepatitis C therapy using Directly Acting Antivirals (DAA) has high efficacy (till 100 %), minimum contra-indications and extraordinarily favorable safety profile. Primarily, it is necessary to pay attention to drug-drug interactions. However they are well documented and successfully resolvable already in general clinical practice. Current possibilities of interferon-free therapy represent combinations of sofosbuvir with other DAA or with ribavirin and combination of paritaprevir boosted by ritonavir + ombitasvir ± dasabuvir (3D combination).